{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:25:57Z","timestamp":1792679157681,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1136\/thoraxjnl-2013-204110","type":"journal-article","created":{"date-parts":[[2014,2,25]],"date-time":"2014-02-25T06:56:51Z","timestamp":1393311411000},"page":"638-647","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":57,"title":["Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma"],"prefix":"10.1136","volume":"69","author":[{"given":"Elizabeth K","family":"Sage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna K","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia Da Silva","family":"Lourenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy L","family":"Kalber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L","family":"Ordidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y C","family":"Gary Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Giangreco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam M","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,2,24]]},"reference":[{"key":"key-10.1136\/thoraxjnl-2013-204110-1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"key-10.1136\/thoraxjnl-2013-204110-2","article-title":"Mesothelioma Register","author":"Executive HaS"},{"key":"key-10.1136\/thoraxjnl-2013-204110-3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/thoraxjnl-2013-204110-4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1510\/icvts.2005.123430","article-title":"The MARS trial: mesothelioma and radical surgery","volume":"5","author":"Treasure","year":"2006","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"key-10.1136\/thoraxjnl-2013-204110-5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1470-2045(04)01492-5","article-title":"Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development","volume":"5","author":"Fennell","year":"2004","journal-title":"Lancet Oncol"},{"key":"key-10.1136\/thoraxjnl-2013-204110-6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"key-10.1136\/thoraxjnl-2013-204110-7","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.1136\/thoraxjnl-2013-204110-8","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1158\/1078-0432.CCR-07-1416","article-title":"A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R) in patients with advanced solid malignancies","volume":"14","author":"Hotte","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-9","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-07-0950","article-title":"Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers","volume":"13","author":"Plummer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","article-title":"Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer","volume":"61","author":"Greco","year":"2008","journal-title":"Lung Cancer"},{"key":"key-10.1136\/thoraxjnl-2013-204110-11","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-09-1267","article-title":"A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1634\/stemcells.2006-0257","article-title":"Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells","volume":"25","author":"Menon","year":"2007","journal-title":"Stem Cells"},{"key":"key-10.1136\/thoraxjnl-2013-204110-13","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1634\/stemcells.2006-0461","article-title":"Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells","volume":"25","author":"Xin","year":"2007","journal-title":"Stem Cells"},{"key":"key-10.1136\/thoraxjnl-2013-204110-14","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","article-title":"Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer","volume":"69","author":"Loebinger","year":"2009","journal-title":"Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-15","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1073\/pnas.0806647106","article-title":"Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy","volume":"106","author":"Sasportas","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key-10.1136\/thoraxjnl-2013-204110-16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ahj.2012.05.026","article-title":"Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial)","volume":"164","author":"Mathiasen","year":"2012","journal-title":"Am Heart J"},{"key":"key-10.1136\/thoraxjnl-2013-204110-17","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/stem.187","article-title":"Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging","volume":"27","author":"Kidd","year":"2009","journal-title":"Stem Cells"},{"key":"key-10.1136\/thoraxjnl-2013-204110-18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/thx.2009.128025","article-title":"Stem cells as vectors for antitumour therapy","volume":"65","author":"Loebinger","year":"2010","journal-title":"Thorax"},{"key":"key-10.1136\/thoraxjnl-2013-204110-19","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1158\/0008-5472.CAN-12-0423","article-title":"FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis","volume":"72","author":"Goldie","year":"2012","journal-title":"Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000113504","article-title":"Characterization of human mesothelioma cell lines as tumor models for suicide gene therapy","volume":"31","author":"Veldwijk","year":"2008","journal-title":"Onkologie"},{"key":"key-10.1136\/thoraxjnl-2013-204110-21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1006\/mthe.2001.0327","article-title":"Human mesenchymal stem cells maintain transgene expression during expansion and differentiation","volume":"3","author":"Lee","year":"2001","journal-title":"Mol Ther"},{"key":"key-10.1136\/thoraxjnl-2013-204110-22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1634\/stemcells.2004-0138","article-title":"Human fetal mesenchymal stem cells as vehicles for gene delivery","volume":"23","author":"Chan","year":"2005","journal-title":"Stem Cells"},{"key":"key-10.1136\/thoraxjnl-2013-204110-23","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/carcin\/bgl069","article-title":"Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs","volume":"27","author":"Chen","year":"2006","journal-title":"Carcinogenesis"},{"key":"key-10.1136\/thoraxjnl-2013-204110-24","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"key-10.1136\/thoraxjnl-2013-204110-25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1378\/chest.12-2094","article-title":"A placebo-controlled, randomized trial of mesenchymal stem cells in COPD","volume":"143","author":"Weiss","year":"2013","journal-title":"Chest"},{"key":"key-10.1136\/thoraxjnl-2013-204110-26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","article-title":"Mesenchymal stem cell homing: the devil is in the details","volume":"4","author":"Karp","year":"2009","journal-title":"Cell Stem Cell"},{"key":"key-10.1136\/thoraxjnl-2013-204110-27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/stem.559","article-title":"Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?","volume":"29","author":"Klopp","year":"2011","journal-title":"Stem Cells"},{"key":"key-10.1136\/thoraxjnl-2013-204110-28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bies.201200087","article-title":"Mesenchymal stem cells for systemic therapy: Shotgun approach or magic bullets?","volume":"35","author":"Millard","year":"2013","journal-title":"Bioessays"},{"key":"key-10.1136\/thoraxjnl-2013-204110-29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1476-4598-6-66","article-title":"Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin","volume":"6","author":"Belyanskaya","year":"2007","journal-title":"Mol Cancer"},{"key":"key-10.1136\/thoraxjnl-2013-204110-30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1165\/ajrcmb.25.1.4472","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines","volume":"25","author":"Liu","year":"2001","journal-title":"Am J Respir Cell Mol Biol"},{"key":"key-10.1136\/thoraxjnl-2013-204110-31","doi-asserted-by":"crossref","first-page":"13021","DOI":"10.1074\/jbc.M709698200","article-title":"Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids","volume":"283","author":"Barbone","year":"2008","journal-title":"J Biol Chem"},{"key":"key-10.1136\/thoraxjnl-2013-204110-32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4048\/jbc.2012.15.3.273","article-title":"Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ","volume":"15","author":"Reagan","year":"2012","journal-title":"J Breast Cancer"},{"key":"key-10.1136\/thoraxjnl-2013-204110-33","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.bjc.6605952","article-title":"TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population","volume":"103","author":"Loebinger","year":"2010","journal-title":"Br J Cancer"},{"key":"key-10.1136\/thoraxjnl-2013-204110-34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1432-0436.1988.tb00806.x","article-title":"Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines","volume":"37","author":"Bepler","year":"1988","journal-title":"Differentiation"},{"key":"key-10.1136\/thoraxjnl-2013-204110-35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/0008-5472.CAN-12-0088","article-title":"NF-kappaB activity regulates mesenchymal stem cell accumulation at tumor sites","volume":"73","author":"Uchibori","year":"2013","journal-title":"Cancer Res"},{"key":"key-10.1136\/thoraxjnl-2013-204110-36","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2249.2006.03064.x","article-title":"Cytokines differentially regulate ICAM-1 and VCAM-1 expression on human gingival fibroblasts","volume":"144","author":"Hosokawa","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"key-10.1136\/thoraxjnl-2013-204110-37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1634\/stemcells.2008-0520","article-title":"Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition","volume":"27","author":"Copland","year":"2009","journal-title":"Stem Cells"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thoraxjnl-2013-204110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T22:17:29Z","timestamp":1601072249000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thoraxjnl-2013-204110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,24]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,6,10]]},"published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1136\/thoraxjnl-2013-204110"],"URL":"https:\/\/doi.org\/10.1136\/thoraxjnl-2013-204110","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,24]]}}}